Catherine Ndichu
Family · Marietta, GANPI 1043870967
Payments from drug & device makers
Across 115 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$574
- AstraZeneca$399
- Pfizer$212
- Novo Nordisk$192
- Kowa Pharmaceuticals America, Inc.$179
- Exact Sciences$128
- plus $717 from 20 others
What the payments were for
- Food & beverage$2,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $574 |
| AstraZeneca | 14 | $399 |
| Pfizer | 11 | $212 |
| Novo Nordisk | 17 | $192 |
| Kowa Pharmaceuticals America, Inc. | 7 | $179 |
| Exact Sciences | 7 | $128 |
| Lilly USA, LLC | 6 | $112 |
| Medtronic | 4 | $88 |
| Neos Therapeutics, LP | 4 | $76 |
| Edwards Lifesciences | 2 | $69 |
| Boehringer Ingelheim | 2 | $43 |
| Dexcom, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Saluda Medical Americas, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Novartis | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| GSK | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,402 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $14,014 |
| MounjaroTirzepatide | 13 | $13,380 |
| Levothyroxine Sodium | 46 | $506 |
| Atorvastatin Calcium | 51 | $475 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $343 |
| Omeprazole | 17 | $223 |
| Famotidine | 18 | $200 |
| Trazodone Hcl | 15 | $177 |
| Metformin Hcl | 21 | $168 |
| Gabapentin | 21 | $164 |
| Amlodipine Besylate | 37 | $153 |
| Lisinopril | 30 | $150 |
| Potassium Chloride | 15 | $128 |
| Escitalopram Oxalate | 11 | $117 |
| Meloxicam | 12 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $192 | $14,01414 claims |
| Lilly USA, LLCMounjaro | $112 | $13,38013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Marietta
- Allie McAllisterMarietta$299K
- Lori ReedMarietta$106K
- Jennifer MekhoukhMarietta$38K
- Janie DinhMarietta$14K
- Erin EsfahaniMarietta$14K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.